1. Scrip
  2. >>Business
  3. >>Financing

Trace Launches With $101m To Pursue ALS Drug Based On Genomic Insights

Could Address Up To 97% Of Patients

 
• By Mandy Jackson

Trace Neuroscience will take its antisense oligonucleotide that restores UNC13A protein production through proper mRNA splicing into the clinic in early 2026.

Trace's lead drug candidate targets UNC13A mRNA splicing to treat ALS (Shutterstock)

Trace Neuroscience emerged from an effort to create a new start-up using genomic insights to discover and develop treatments for amyotrophic lateral sclerosis (ALS). The company’s founders focused on the UNC13A protein, improper production of which drives synaptic dysfunction and disrupted neuronal signaling in nearly all ALS patients. Now, Trace has come out of stealth mode with $101m in series A venture capital to test its drug in patients.

Key Takeaways
  • Trace Neuroscience launched with $101m in series A funding to support its development of an antisense oligonucleotide (ASO) targeting UNC13A mRNA splicing in the treatment...

Co-founder and CEO Eric Green told Scrip that Trace plans to initiate a clinical trial for its antisense oligonucleotide (ASO) in early 2026 with the new funding announced on 12...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

 
• By Mandy Jackson

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

More from Scrip

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.